Endo Pharmaceuticals

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Endo Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count).

23 total trials none currently recruiting 22 completed top decile by trial count

Endo Pharmaceuticals: 23 sponsored US clinical trials, none currently recruiting.

Endo Pharmaceuticals sponsors 23 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 22 completed. 12 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Edematous Fibrosclerotic Panniculopathy, with 4 trials.

Top-decile sponsor footprint

Endo Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

22 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

23 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 3

Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)

NCT06151197
COMPLETED Phase 2

Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks

NCT05419505
COMPLETED Phase 3

Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis

NCT05254457
COMPLETED

Long-term Durability Study of Collagenase Clostridium Histolyticum (CCH)

NCT04381117
COMPLETED Phase 3

Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)

NCT03526549
COMPLETED Phase 2

Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules

NCT02193828
COMPLETED Phase 2

Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder

NCT02006719
COMPLETED Phase 2

A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy

NCT01987986
COMPLETED Phase 1

Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

NCT01774435
COMPLETED Phase 1

The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

NCT01518907
COMPLETED Phase 2

AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder

NCT01483963
COMPLETED

Retrospective Chart Review of Valstar

NCT01304173
COMPLETED Phase 3

Study of AA4500 in the Treatment of Peyronie's Disease

NCT01221623
COMPLETED Phase 3

Study of AA4500 in the Treatment of Peyronie's Disease

NCT01221597
COMPLETED Phase 3

AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease

NCT00528424
COMPLETED Phase 1

A Pharmacokinetic Study of AA4500 (XIAFLEX™, Proposed Name) in Subjects With Dupuytren's Contracture

NCT00528931
COMPLETED Phase 3

Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain

NCT00226421
COMPLETED Phase 3

Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain

NCT00226395
COMPLETED Phase 4

Pilot Study of the Efficacy and Safety of Lidoderm Patch in the Treatment of Low Back Pain

NCT00904475
COMPLETED Phase 4

A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions

NCT00904202
COMPLETED Phase 4

Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy

NCT00903851
COMPLETED Phase 4

Topical Lidocaine Patch in Low Back Pain

NCT00904540
COMPLETED Phase 2

Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)

NCT01316874

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 6
Phase 3 8
Phase 4 4

Therapeutic Areas

Edematous Fibrosclerotic Panniculopathy 4
Cellulite 3
Peyronie's Disease 2
Plantar Fibromatosis 2
Frozen Shoulder 2
Adhesive Capsulitis 2
Advanced Dupuytren's Disease 1
Carcinoma in Situ of Bladder 1
Edematous Fibrosclerotic Panniculopathy (EFP) 1
Idiopathic Sensory Neuropathy 1

How the Endo Pharmaceuticals archive is shaped

23 indexed studies, none listed as recruiting (0% open); 22 completed (96%).

Phase mix: 12 late (III/IV) vs 9 early (I/II) (balanced across stages).

Top condition: Edematous Fibrosclerotic Panniculopathy (4 trials), 9 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Endo Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 23 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Endo Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0510152025 0%5%10%15%20%25% Total trials Recruiting share Endo PharmaceuticalsAMAG PharmaceuticalsAtriCureCara TherapeuticsCraig L Slingluff, Jr10xBio22nd Century Group23andMe3-C Institute for Social Development
Endo Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Endo Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 23 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Endo Pharmaceuticals page

23 registered trials is a research-attention snapshot, not an endorsement of Endo Pharmaceuticals or any single study.

  • None of Endo Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Edematous Fibrosclerotic Panniculopathy is the condition Endo Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Edematous Fibrosclerotic Panniculopathy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Endo Pharmaceuticals pipeline card: 23 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.